| Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study AK Fielding, SM Richards, R Chopra, HM Lazarus, MR Litzow, G Buck, ... Blood 109 (3), 944-950, 2007 | 908 | 2007 |
| Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide AEA Lopez-Girona, D Mendy, T Ito, K Miller, AK Gandhi, J Kang, ... Leukemia 26 (11), 2326-2335, 2012 | 859 | 2012 |
| Lenalidomide induces ubiquitination and degradation of CK1α in del (5q) MDS J Krönke, EC Fink, PW Hollenbach, KJ MacBeth, SN Hurst, ND Udeshi, ... Nature 523 (7559), 183-188, 2015 | 799 | 2015 |
| Challenges to curing primary brain tumours K Aldape, KM Brindle, L Chesler, R Chopra, A Gajjar, MR Gilbert, ... Nature reviews Clinical oncology 16 (8), 509-520, 2019 | 671 | 2019 |
| Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin … AK Gandhi, J Kang, CG Havens, T Conklin, Y Ning, L Wu, T Ito, H Ando, ... British journal of haematology 164 (6), 811-821, 2014 | 635 | 2014 |
| In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation PD Kottaridis, DW Milligan, R Chopra, RK Chakraverty, S Chakrabarti, ... Blood, The Journal of the American Society of Hematology 96 (7), 2419-2425, 2000 | 603 | 2000 |
| Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis RNVS Suragani, SM Cadena, SM Cawley, D Sako, D Mitchell, R Li, ... Nature medicine 20 (4), 408-414, 2014 | 455 | 2014 |
| Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen R Chakraverty, K Peggs, R Chopra, DW Milligan, PD Kottaridis, ... Blood, The Journal of the American Society of Hematology 99 (3), 1071-1078, 2002 | 400 | 2002 |
| Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation KS Peggs, A Hunter, R Chopra, A Parker, P Mahendra, D Milligan, ... The Lancet 365 (9475), 1934-1941, 2005 | 346 | 2005 |
| Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity PH Schafer, A Parton, L Capone, D Cedzik, H Brady, JF Evans, HW Man, ... Cellular signalling 26 (9), 2016-2029, 2014 | 339 | 2014 |
| Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma E Morris, K Thomson, C Craddock, P Mahendra, D Milligan, G Cook, ... Blood 104 (13), 3865-3871, 2004 | 321 | 2004 |
| An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia M Dussiot, TT Maciel, A Fricot, C Chartier, O Negre, J Veiga, D Grapton, ... Nature medicine 20 (4), 398-407, 2014 | 320 | 2014 |
| Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT C Crawley, M Lalancette, R Szydlo, M Gilleece, K Peggs, S Mackinnon, ... Blood 105 (11), 4532-4539, 2005 | 285 | 2005 |
| The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation DI Marks, R Lush, J Cavenagh, DW Milligan, S Schey, A Parker, FJ Clark, ... Blood, The Journal of the American Society of Hematology 100 (9), 3108-3114, 2002 | 266 | 2002 |
| Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study R Chopra, JD Eaton, A Grassi, M Potter, B Shaw, C Salat, P Neumeister, ... British journal of haematology 111 (4), 1122-1129, 2000 | 241 | 2000 |
| The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases L Tatton, GM Morley, R Chopra, A Khwaja Journal of Biological Chemistry 278 (7), 4847-4853, 2003 | 231 | 2003 |
| Mesenchymal stem cells as vehicles for gene delivery. JD Mosca, JK Hendricks, D Buyaner, J Davis-Sproul, LC Chuang, ... Clinical Orthopaedics and Related Research (1976-2007) 379, S71-S90, 2000 | 215 | 2000 |
| Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 CC Bjorklund, L Lu, J Kang, PR Hagner, CG Havens, M Amatangelo, ... Blood cancer journal 5 (10), e354-e354, 2015 | 208 | 2015 |
| Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF 4 and cereblon expression LH Zhang, J Kosek, M Wang, C Heise, PH Schafer, R Chopra British journal of haematology 160 (4), 487-502, 2013 | 198 | 2013 |
| Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response A Lopez‐Girona, D Heintel, LH Zhang, D Mendy, S Gaidarova, H Brady, ... British journal of haematology 154 (3), 325-336, 2011 | 194 | 2011 |
